World’s Largest Respiratory Genetics Study Launches on World COPD Day
News Nov 15, 2012
The main aims of the study will be to discover what determines an individual’s lung health and why smoking harms the lungs of some people more than others.
The scientists, from the University of Nottingham, the University of Leicester, and St George’s, University of London, hope to find out why some people are genetically more prone to suffer from lung disease, particularly chronic obstructive pulmonary disease (COPD). COPD includes conditions such as chronic bronchitis and emphysema and is the sixth most common cause of death in the UK (around 30,000 deaths per year). It affects approximately 900,000 people in the UK and costs the NHS £500m every year.
The World Health Organization (WHO) estimates that COPD is the fourth leading cause of death worldwide (after coronary heart disease, cerebrovascular disease and acute respiratory infection) but it is predicted to move into third place in the near future. Wednesday 14 November is World COPD Day.
The project aims to discover the genes which affect lung function, and also those which may affect the chances of developing lung disease for both smokers and non-smokers. It will also investigate whether genes play a part in the ability, or the failure, to maintain good lung health for both smokers and non-smokers. The researchers will also be able to investigate genetic factors that may affect the likelihood of an individual becoming addicted to smoking.
The study, which is called UK BiLEVE (UK Biobank Lung Exome Variant Evaluation), will be one of the first projects to make use of UK Biobank which holds health and lifestyle information from half a million volunteers and is the world’s largest data resource of its kind.
All UK Biobank participants have already had their lung function measured and given information about their smoking habits, past and present. They have also provided blood samples which can be used to extract genetic information. In this study researchers will use the anonymous data from 50,000 of these participants to determine genetic variants associated with susceptibility to COPD. They will look at both rare and common single nucleotide polymorphisms (tiny variations in genes) in the participants’ DNA and the lung function of those who are heavy smokers and those who have never smoked.
Lead researcher and Dean of Nottingham Medical School, Professor Ian Hall, says: “We currently know very little about why there is such a wide difference in lung health even among smokers. It may have something to do with genetics so we’re extremely excited about using the unique resource of UK Biobank to test this theory. This study couldn’t be done anywhere else in the world.”
Professor David Lomas, Chair of the MRC Population and Systems Medicine Board, says: “We know that smoking is unhealthy for anyone but we know little about why the lungs of most smokers are seriously affected, while those of some seem to stay relatively healthy. If we knew more about the genetics that cause this variation we would be better able to direct treatments to those who are most at risk and have an increased chance of developing drugs to target this type of lung disease.”
Professor Sir Rory Collins, UK Biobank Principal Investigator, said: “We are extremely grateful to the half a million people throughout Britain who went out of their way to join UK Biobank. Their commitment will provide key insights into a wide range of illnesses that kill and cause pain and suffering. Last week we heard of plans to use UK Biobank to study dementia. This week UK Biobank helps scientists tackle a serious lung condition. UK Biobank will become a key resource to improve health in the 21st century. We are grateful to the MRC, Wellcome Trust and Department of Health for having the vision to back such an initiative.”
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE